About Ovoca Bio

Ovoca Bio is a clinical-stage biopharmaceutical company focused on women’s health. In 2018 the Company acquired control of IVIX, a biotechnology company developing BP-101, a novel medicinal treatment for premenopausal women with hypoactive sexual desire disorder (HSDD). Since the initial acquisition, Ovoca Bio has supported the continued clinical development and commercial planning of BP-101, which has been submitted for marketing authorisation in Russia and will shortly commence a Phase 2 study in a western population with HSDD. In March 2020, BP-101 became a fully owned program of Ovoca Bio.

Founded and incorporated in Ireland, the business currently operates in Ireland, the UK and Russia.

Our Vision & Approach

Ovoca Bio’s vision is to become a leader in the research and development of, and commercial partner of choice for, novel medicines in areas of high unmet need that affect women.

The Company has filed for approval for the marketing of BP-101 in Russia and has commenced development of the drug for major global markets, with special focus on the US and Europe.

Ovoca Bio will consider opportunities to license commercialisation rights and/or collaborate with global pharmaceutical companies, regional partners or other qualified potential partners where they would accelerate the availability of current plus future product candidates to patients in need.

Ovoca Bio owns a patent portfolio that provides broad effective protection of its technology and lead product candidate. The Company intends to continue to leverage this patent portfolio and selectively add to it, to develop and commercialise its initial product candidate and potentially future ones.

European-based biopharmaceutical company with a focus on women’s health

Currently developing BP-101 a novel synthetic peptide for treatment of women with hypoactive sexual desire disorder (HSDD)

€16.5 million in cash and liquid assets to support drug development activities company with a focus on women’s health

European-based biopharmaceutical company with a focus on women’s health

Management Team

Kirill Golovanov

Chief Executive Officer

Christopher Wiltshire

Chief Business Officer (interim)

Dr. Daniil Nemenov

SVP, Clinical Development & Operations

Dr. Mikhail Lomonosov

VP, Research & CMC

Dr. Alexey Matckevich

VP Preclinical

Dmitriy Nikitashenko

VP Finance

Board of Directors

Mikhail Mogutov

Executive Chairman

Kirill Golovanov

Chief Executive Officer

Christopher Wiltshire

Non-Executive Director

Romulo Colindres

Non-Executive Director

Timothy McCutcheon

Non-Executive Director

Leonid Skoptsov

Non-Executive Director